| |||||||||||||||
| Rating | Health Concerns |
|---|---|
![]() |
|
![]() |
|
![]() |
|
Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary
studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but
minimal or no scientific evidence. For a supplement, little scientific support and/or minimal
health benefit. | |
The typical recommendation is 140 to 360 mg per day. Most studies have used 200 mg daily.
No significant adverse effects have been reported with tocotrienols.17
Are there any drug
interactions?
Certain medicines may interact with tocotrienols. Refer to drug interactions for a list of those medicines.
1. Kamal-Eldin A, Appelqvist LA. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids 1996;31:671–701 [review].
2. Kamat JP, Devasagayam TPA. Tocotrienols from palm oil as potent inhibitors of lipid peroxidation and protein oxidation in rat brain mitochondria. Neurosci Lett 1995;195:179–82.
3. Theriault A, Chao JT, Wang Q, et al. Tocotrienol: a review of its therapeutic potential. Clin Biochem 1999;32:309–19 [review].
4. Suarna C, Hood RL, Dean RT, Stocker R. Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins. Biochim Biophys Acta 1993;1166:163–70.
5. Tomeo AC, Geller M, Watkins TR, et al. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids 1995;30:1179–83.
6. Parker RA, Pearce BC, Clark RW, et al. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem 1993;268:11230–8.
7. Pearce BC, Parker RA, Deason ME, et al. Hypocholesterolemic activity of synthetic and natural tocotrienols. J Med Chem 1992;35:3595–606.
8. Qureshi AA, Bradlow BA, Brace L, et al. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids 1995;30:1171–7.
9. Qureshi AA, Qureshi N, Wright JJ, et al. Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am J Clin Nutr 1991;53:1021S–6S.
10. Wahlqvist ML, Krivokuca-Bogetic A, Lo CS, et al. Differential serum response of tocopherols and tocotrienols during vitamin supplementation in hypercholesterolemic individuals without change in coronary risk factors. Nutr Res 1992;12:S181–201.
11. Mensink RP, van Houwelingen AC, Kromhout D, Hornstra G. A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am J Clin Nutr 1999;69:213–9.
12. Goh SH, Hew NF, Norhanom AW, Yadav M. Inhibition of tumour promotion by various palm-oil tocotrienols. Int J Cancer 1994;57:529–31.
13. Yu W, Simmons-Menchaca M, Gapor A, et al. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. Nutr Cancer 1999;33:26–32.
14. Mo H, Elson CE. Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. J Nutr 1999;129:804–13.
15. Nesaretnam K, Stephen R, Dils R, Darbre P. Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. Lipids 1998;33:461–9.
16. He L, Mo H, Hadisusilo S, et al. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr 1997;127:668–74.
17. Theriault A, Chao JT, Wang Q, et al. Tocotrienol: a review of its therapeutic potential. Clin Biochem 1999;32:309–19 [review].
| |||||||